´ëÇѼºÇü¾È°úÇÐȸ [¿Â¶óÀÎ] Á¦2ȸ °³¿øÀÇ ¼±»ý´Ô°ú Àü°øÀÇ ¼±»ý´ÔÀ» À§ÇÑ Áõ·Ê ½ÉÆ÷Áö¾ö : 2021-12-05±³À°ÀÏÀÚ : 2021-12-05
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
[¿Â¶óÀÎ] Á¦2ȸ °³¿øÀÇ ¼±»ý´Ô°ú Àü°øÀÇ ¼±»ý´ÔÀ» À§ÇÑ Áõ·Ê ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѼºÇü¾È°úÇÐȸ
´ã´çÀÚ : ÀÌÁ¤±Ô
¿¬¶ôó : 02-6299-1688
À̸ÞÀÏ :
ksoprs@naver.com ±³À°Á¾·ù : ¾È°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í ¼ºÇü¾È°úÇÐȸ Á¤È¸¿ø-¼ö·Ãº´¿ø ºÀÁ÷ÀÇ ¹«·á, ±×¿Ü 20,000¿ø¼ºÇü¾È°úÇÐȸ ÁØȸ¿ø-¼ö·Ãº´¿ø ºÀÁ÷ÀÇ 10,000¿ø, ±×¿Ü 30,000¿ø¾È°úÇÐȸ Á¤È¸¿ø-40,000¿øÀü°øÀÇ, ±ºÀÇ°ü, °øº¸ÀÇ, ÀüÀÓÀÇ, ÀÓ»ó°»ç - 10,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 12-05 08:30~08:55 µî·Ï ¾øÀ½(¾øÀ½)
±âŸ 12-05 08:55~09:00 Àλ縻 ¾ÈÈñ¹è±³¼ö´Ô(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 12-05 09:00~09:10 º¸Á¸Àû Ä¡·á, ´«½çÂñ¸² ÇÕº´Áõ case, ¼ö¼úÀº ¾ðÁ¦ ÇÏ´Â°Ô ÁÁÀºÁö.. ¹éÁö¼±(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 12-05 09:10~09:20 ³ëÀμº vs ocular MG, phenylephrine test, anterior Vs posterior approach Àå¼±¿µ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 12-05 09:20~09:30 ´Ù·¡³¢ Ä¡·á, TA injection, I and C, persistent lid edema TA injection, ÀÚ°¡Áö¹æ ÁÖ»çÈÄ lipogranuloma Áø´Ü ¹× Ä¡·á ¾ÈÁ¤È¿(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 12-05 09:30~09:40 ÀÚÁÖÁ¢ÇÏ´Â ¾ç¼º ¹× ¾Ç¼º À§ÁÖ 3~4 cases, ¼ö¼úÀû Ä¡·á ÀüÈÄ »çÁø ¹× µ¿¿µ»ó Á¶¿ø°æ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 12-05 09:40~09:50 Àç°Ç¹æ¹ýÀÇ ¼±ÅÃ, ¼ö¼ú¹ý »çÈ£¼®(¿ï»êÀÇ´ë)
±³À°½Ã°£ 12-05 09:50~10:00 lower lid blepharoplasty ÀÌÈÄ ÇÕº´Áõ ±è¼ºÃ¶(Çѱæ¾È°ú)
±³À°½Ã°£ 12-05 10:00~10:10 °³¿ø°¡¿¡¼ ÇÒ¼ö ÀÖ´Â º¸Å彺 ÀûÀÀÁõ°ú ÁÖ»ç ¹æ¹ý µ¿¿µ»ó ÀÌÁÖÇâ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 12-05 10:10~10:20 Áø´Ü(FDDT), ¸¶»çÁö ¹æ¹ý, probing ³ëÇÏ¿ì, ST À̳ª DCR ÇÊ¿äÇß´ø Áõ·Ê ÀÌÃæÇö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 12-05 10:20~10:30 ½Ã¼ú ÀûÀÀÁõ, ½ÇÁ¦½Ã¼ú ¿µ»ó ¹× ½Ã¼úÆÁ, °³¿ø°¡¿¡¼ false passage ¸¸µç Áõ·Ê Àå¹Î¿í(µ¿±¹ÀÇ´ë)
Åä·Ð 12-05 10:30~10:50 Q&A À̼ºº¹(Ãæ³²ÀÇ´ë)
ÈÞ½Ä 12-05 10:50~11:00 ÈÞ½Ä ()
±³À°½Ã°£ 12-05 11:00~11:10 preseptal vs orbital cellulitis ¹× ¾î¶² °æ¿ì »ó±Þº´¿ø Àü¿ø ÇÊ¿äÇÑÁö/°³¿ø°¡¿¡¼ º¼¼ö ÀÖ´Â injection Áõ·Ê¿Í ó¹æÀÇ ±¸Ã¼ÀûÀÎ ¿¹ ÇÑÁö»ó(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 12-05 11:10~11:20 Noninfectious inflammatory disease Áõ·Êµé (IOI, sclerosing, IgG4, Wegener¡¦) ½ÅÇöÁø(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 12-05 11:20~11:30 ´Ù¾çÇÑ ¾È¿ÍÁ¾¾çÀÇ ¿µ»óÀû °¨º° ÃÖ¿¬ÁÖ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 12-05 11:30~11:40 AJCC criteria º°·Î Áõ·Ê(°á¸· ¹× ¾È¿Í)º¸¿©ÁÖ°í, °æ°ú Áß Àç¹ßÀ̳ª ÀüÀÌ ÀÖ¾ú´ø Áõ·Êµé. À̹ÎÁ¤(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 12-05 11:40~11:50 Á¾¾ç Á¾·ù, À§Ä¡, ¼º»ó¿¡ µû¸¥ ¼ö¼ú Á¢±Ù¹ý ¼±Åà ¹æ¹ý À§ÁÖ ¼Áö¿ø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 12-05 11:50~12:00 dysthyroid optic neuropathy, exposure keratitis, diplopia/strabismus ¾î¶»°Ô Ä¡·áÇÏ´ÂÁö Áõ·Ê °íÀç»ó(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 12-05 12:00~12:10 ³ªÀÌ, CT ¼Ò°ß º°·Î »ó±Þº´¿ø refer¿©ºÎ¿Í ¼ö¼ú¿©ºÎ °áÁ¤ (ƯÈ÷ ¼Ò¾Æ¾È¿Í°ñÀý°ú EOM incarceration) ÀÌÈ(°í·ÁÀÇ´ë)
Åä·Ð 12-05 12:10~12:30 Q&A ¾È¹Î(ÀüºÏÀÇ´ë)